Skip to main content
Addgene

Somatic Gain of KRAS Function in the Endothelium is Sufficient to Cause Vascular Malformations that Require MEK but not PI3K Signaling.

Fish JE, Flores-Suarez CP, Boudreau E, Herman AM, Gutierrez MC, Gustafson D, DiStefano PV, Cui M, Chen Z, Berman De Ruiz K, Schexnayder TS, Ward CS, Radovanovic I, Wythe JD
Circ Res. 2020 Jun 17. doi: 10.1161/CIRCRESAHA.119.316500. (Link opens in a new window) PubMed (Link opens in a new window) Article

Plasmids from Article

ID Plasmid Purpose
156402JDW 743 (pDONR221-EYFP-hKRAS4B-WT)Gateway middle entry clone encoding EYFP-fused to human KRAS4B, includes a stop codon
156403JDW 742 (pDONR221-EGFP-KRAS4B-G12V)Gateway middle entry clone encoding EGFP-fused to human KRAS4B with G12V mutation, includes a stop codon
156404JDW 832 (pDONR221-V5-mTagBFP2-KRAS4A-G12D)Gateway middle entry clone encoding V5-tagged mTagBFP2-fused to human KRAS4A with G12D mutation, includes a stop codon
156405JDW 822 (pDONR221-V5-mScarlet-I-KRAS4A-WT)Gateway middle entry clone encoding V5-tagged mScarlet-I-fused to human KRAS4A, includes a stop codon
156406JDW 823 (pDONR221-V5-mScarlet-I-hsKRAS4A-G12V)Gateway middle entry clone encoding V5-tagged mScarlet-I-fused to human KRAS4A with G12V mutation, includes a stop codon
156407JDW 762 (pCS2-EGFP-hsKRAS4B-G12V)pCS2 CMV expression vector driving EGFP fused human KRAS4B-G12V
156408JDW 763 (pCS2-EYFP-hsKRAS4B-WT)pCS2 CMV expression vector driving EYFP fused human KRAS4B
156409JDW 827 (pCS2-V5-mTagBFP2-hsKRAS4A-G12D)pCS2 CMV expression vector driving V5-tagged mTagBFP2 fused human KRAS4A-G12D
156410JDW 837 (pCS2-V5-mScarlet-I-hsKRAS4A-G12V)pCS2 CMV expression vector driving V5-tagged mScarlet-I-fused human KRAS4A-G12V
156411JDW 836 (pCS2-V5-mScarlet-I-hsKRAS4A-WT)pCS2 CMV expression vector driving V5-tagged mScarlet-I-fused human KRAS4A
156412JDW 295 (pDONR-Dll4-F2-ETS#2-WT-8X)Gateway middle entry clone containing an 8X multimerized ETS#2 DNA binding site from the murine Dll4 intronic enhancer
156413JDW 771 (pTol2-kdrl:EYFP-hsKRAS4B-WT-ac/Y)kdrl promoter driving EYFP fused to human KRAS4B with an alpha-crystallin zsYellow reporter flanked by Tol2 sites
156414JDW 770 (pTol2-kdrl:EGFP-hsKRAS4B-G12V-ac/Y)kdrl promoter driving EGFP fused to human KRAS4B-G12V with an alpha-crystallin Venus (YFP) reporter flanked by Tol2 sites
156415JDW 829 (pTol2-kdrl:V5-mTagBFP2-hsKRAS4A-G12D-ac/Y)kdrl promoter driving V5-tagged mTagBFP2 fused to human KRAS4A-G12D with an alpha-crystallin Venus (YFP) reporter flanked by Tol2 sites
156416JDW 859 (pTol2-kdrl:V5-mScarlet-I-hsKRAS4A-G12V-ac/mC)kdrl promoter driving V5-tagged mScarlet-I fused to human KRAS4A-G12V with an alpha-crystallin mCerulean reporter flanked by Tol2 sites
156417JDW 249 (pTol2-Dll4-F2-ETS#2-WT-8X-E1b-EGFP)8X copies of the ETS#2 site of the murine Dll4 intronic enhancer and a minimal E1b reporter driving expression of EGFP flanked by Tol2 sites
180468JDW 858 (pTol2-Kdrl-V5-mScarlet-KRAS4A-WT--AC-Cerulean)kdrl promoter driving V5-tagged mScarlet-I fused to human KRAS4A with an alpha-crystallin mCerulean reporter flanked by Tol2 sites

Antibodies from Article